In a welcome move, Cardinal Health stock saw its Relative Strength Rating rise from 65 to 71 on Friday.
This proprietary rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History shows that the stocks that go on to make the biggest gains tend to have an 80 or higher RS Rating in the early stages of their moves. See if Cardinal Health stock can continue to rebound and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
Is Cardinal Health Stock A Buy?
Cardinal Health stock is in a buy range after clearing a 116.05 entry in a flat base. The proper buying range is up to 5% above the initial entry. Once a stock hits that benchmark, it's best to hold off investing and wait for it to set up another buying opportunity..
The Dublin, Ohio-based pharmaceuticals and specialty products provider reported 9% EPS growth in its most recent report. Sales increased -4%.
Cardinal Health stock earns the No. 4 rank among its peers in the Medical-Wholesale Drugs industry group. Cencora is the top-ranked stock within the group.
